Crocin nano-chitosan-coated compound improves anxiety disorders, learning, and spatial memory in Alzheimer’s model induced by beta-amyloid in rats

Document Type : Original Article

Authors

1 Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): Alzheimer’s disease (AD) is a neurodegenerative disease that results in the gradual breakdown of brain tissue, causing the deterioration of intellectual function and ability. Crocin is a saffron carotenoid compound proven to have excellent neuroprotective and anti-inflammation properties, although it has some limitations such as low stability and bioavailability. Therefore, in the current research, we tried to improve these limitations by using nanotechnology and chitosan as the carrier. Our study examined the therapeutic effects of crocin nano-chitosan-coated compound and compared it with intact crocin in lower dosages than other studies in AD rat models. 
Materials and Methods: Encapsulating crocin into chitosan nanoparticles was done through a modified technique to improve its limitations. The AD rat model was induced by bilaterally injecting beta-amyloid (Aβ) peptide into the frontal lobe using a stereotaxic device. To evaluate memory, we conducted the Barnes maze test, and to evaluate anxiety, we used the elevated plus maze test. Also, histological tests were conducted to evaluate neuronal damage in each group. 
Results: Crocin nano-chitosan-coated administration significantly improved specific memory indicators compared to the Aβ and other treated groups. A significant decrease in anxiety indicators was detected compared to the Aβ and other treated groups. Finally, the results of hippocampus staining indicated a meaningful difference between the Aβ group and other treated groups, compared to the crocin nano-chitosan-coated group. 
Conclusion: Treatment with low dosages of crocin in the nano-coated form exhibited great efficacy in reducing AD’s adverse effects compared to the same dosage of intact crocin.

Keywords

Main Subjects

References

1. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1:a006189.
2. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol 2012; 3:73-93.
3. Liang C-S, Li D-J, Yang F-C, Tseng P-T, Carvalho AF, Stubbs B, et al. Mortality rates in Alzheimer’s disease and non-Alzheimer’s dementias: a systematic review and meta-analysis. Lancet Healthy Longev 2021; 2:e479-e488.
4. Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, et al. Subregional hippocampal atrophy predicts Alzheimer’s dementia in the cognitively normal. Neurobiol Aging 2010; 31:1077-1088.
5. Duyckaerts C, Delatour B, Potier M-C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009; 118:5-36.
6. Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 2020; 27:1-13.
7. Nguyen TT, Nguyen TTD, Nguyen TKO, Vo TK. Advances in developing therapeutic strategies for Alzheimer’s disease. Biomed Pharmacother 2021; 139:111623.
8. Miziak B, Błaszczyk B, Czuczwar SJ. Some candidate drugs for pharmacotherapy of Alzheimer’s disease. Pharmaceuticals 2021; 14:458.-491.
9. Yousefsani BS, Mehri S, Pourahmad J, Hosseinzadeh H. Protective effect of crocin against mitochondrial damage and memory deficit induced by beta-amyloid in the Hippocampus of rats. Iran J Pharm Res 2021; 20:79-94.
10. Salek R, Dehghani M, Mohajeri SA, Talaei A, Fanipakdel A, Javadinia SA. Amelioration of anxiety, depression, and chemotherapy related toxicity after crocin administration during chemotherapy of breast cancer: a double blind, randomized clinical trial. Phytotherapy Research 2021; 35:5143-5153.
11. Hadipour M, Meftahi GH, Afarinesh MR, Jahromi GP, Hatef B. Crocin attenuates the granular cells damages on the dentate gyrus and pyramidal neurons in the CA3 regions of the hippocampus and frontal cortex in the rat model of Alzheimer’s disease. J Chem Neuroanat 2021; 113:101837.
12. Heidari S, Mehri S, Hosseinzadeh H. Memory enhancement and protective effects of crocin against D-galactose aging model in the hippocampus of Wistar rats. Iran J Basic Med Sci 2017; 20:1250-1259.
13. Asalgoo S, Pirzad Jahromi G, Hatef B, Sahraei H. The effect of saffron aqueous extract and crocin on PTSD rat models: The focus on learning and spatial memory. J Adv Med Biomed Res 2018; 26:34-42.
14. Abdullaev F, editor Biological properties and medicinal use of saffron (Crocus sativus L.). II International Symposium on Saffron Biology and Technology 739; 2006.
15. ZHANG C-F. Research progress on pharmacokinetics and dosage forms of crocin and crocetin. Zhong Cao Yao 2019:234-242.
16. Rahaiee S, Hashemi M, Shojaosadati SA, Moini S, Razavi SH. Nanoparticles based on crocin loaded chitosan-alginate biopolymers: Antioxidant activities, bioavailability and anticancer properties. Int J Biol Macromol 2017; 99:401-408.
17. Rahaiee S, Shojaosadati SA, Hashemi M, Moini S, Razavi SH. Improvement of crocin stability by biodegradeble nanoparticles of chitosan-alginate. Int J Biol Macromol 2015; 79:423-432.
18. Nasrpour S, Yousefi G, Niakosari M, Aminlari M. Nanoencapsulation of saffron crocin into chitosan/alginate interpolyelectrolyte complexes for oral delivery: A Taguchi approach to design optimization. J Food Sci 2022; 87:1148-1160.
19. Kurakula M, Gorityala S, Patel DB, Basim P, Patel B, Kumar Jha S. Trends of chitosan based delivery systems in neuroregeneration and functional recovery in spinal cord injuries. Polysaccharides 2021; 2:519-537.
20. Yu S, Xu X, Feng J, Liu M, Hu K. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. Int J Pharm 2019; 560:282-293.
21. Manek E, Darvas F, Petroianu GA. Use of biodegradable, chitosan-based nanoparticles in the treatment of Alzheimer’s disease. Molecules 2020; 25:4866.
22. Sarvaiya J, Agrawal Y. Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery. Int J Biol Macromol 2015; 72:454-465.
23. Wazed A, Rajendran S, Joshi M. Synthesis and characterization of chitosan and silver loaded chitosan nanoparticles for bioactive polyester. Carbohydr Polym 2011; 83:438-446.
24. Hadipour M, Kaka G, Bahrami F, Meftahi GH, Pirzad Jahromi G, Mohammadi A, et al. Crocin improved amyloid beta induced long‐term potentiation and memory deficits in the hippocampal CA1 neurons in freely moving rats. Synapse 2018; 72:e22026.
25. Dudhani AR, Kosaraju SL. Bioadhesive chitosan nanoparticles: Preparation and characterization. Carbohydr Polym 2010; 81:243-251.
26. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2007; 2:322-328.
27. Pourkhodadad S, Oryan S, Hadipour MM, Kaka G, Sadraie SH. Minocycline enhance the restorative ability of olfactory ensheathing cells by the upregulation of BDNF and GDNF expression after spinal cord injury. Basic Clin Neurosci 2021; 12:777-788.
28. Zaqout S, Kaindl AM. Golgi-Cox staining step by step. Front Neuroanat 2016; 10:38.
29. Watson C. The Rat Brain in Stereotaxic Coordinates: Hard Cover Edition: Academic press; 2007.
30. Wang C, Cai X, Hu W, Li Z, Kong F, Chen X, et al. Investigation of the neuroprotective effects of crocin via antioxidant activities in HT22 cells and in mice with Alzheimer’s disease. IInt J Mol Med 2019; 43:956-966.
31. Farkhondeh T, Samarghandian S, Yazdi HS, Samini F. The protective effects of crocin in the management of neurodegenerative diseases: a review. Am J Neurodegener Dis 2018; 7:1.
32. Gudarzi S, Jafari M, Pirzad Jahromi G, Eshrati R, Asadollahi M, Nikdokht P. Evaluation of modulatory effects of saffron (Crocus sativus L.) aqueous extract on oxidative stress in ischemic stroke patients: a randomized clinical trial. Nutr Neurosci 2022; 25:1137-1146.
33. Salama RM, Abdel-Latif GA, Abbas SS, Hekmat M, Schaalan MF. Neuroprotective effect of crocin against rotenone-induced Parkinson’s disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221. Neuropharmacology 2020; 164:107900.
34. Jahromi GP, Khodadadi H, Fasihi-Ramandi M, Esmaeili M, Shahriary A. Neuroprotective and antiapoptotic effects of N-acetylcystein and crocus sativus aqueous extract on arsenic-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. Indian J Pharm Educ Res 2019; 53:695-702.
35. Adabizadeh M, Mehri S, Rajabpour M, Abnous K, Rashedinia M, Hosseinzadeh H. The effects of crocin on spatial memory impairment induced by hyoscine: Role of NMDA, AMPA, ERK, and CaMKII proteins in rat hippocampus. Iran J Basic Med Sci 2019; 22:601-609.
36. Asalgoo S, Tat M, Sahraei H, Pirzad Jahromi G. The psychoactive agent crocin can regulate hypothalamic-pituitary-adrenal axis activity. Front Neurosci 2017; 11:668-677.
37. Zhang L, Previn R, Lu L, Liao R-F, Jin Y, Wang R-K. Crocin, a natural product attenuates lipopolysaccharide-induced anxiety and depressive-like behaviors through suppressing NF-kB and NLRP3 signaling pathway. Brain Res Bull 2018; 142:352-359.
38. Ghalandari-Shamami M, Nourizade S, Yousefi B, Vafaei AA, Pakdel R, Rashidy-Pour A. Beneficial effects of physical activity and crocin against adolescent stress induced anxiety or depressive-like symptoms and dendritic morphology remodeling in prefrontal cortex in adult male rats. Neurochem Res 2019; 44:917-929.
39. Van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, Filippis DD, et al. Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 2006; 63:1410-1424.
40. Fabiano A, De Leo M, Cerri L, Piras AM, Braca A, Zambito Y. Saffron extract self-assembled nanoparticles to prolong the precorneal residence of crocin. J Drug Deliv Sci Technol 2022; 74:103580.
41. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 2007; 59:24-34.
42. Zussy C, Brureau A, Keller E, Marchal S, Blayo C, Delair B, et al. Alzheimer’s disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats. PLoS One 2013; 8:e53117.
43. Hadipour M, Bahari Z, Afarinesh MR, Jangravi Z, Shirvani H, Meftahi GH. Administering crocin ameliorates anxiety‐like behaviours and reduces the inflammatory response in amyloid‐beta induced neurotoxicity in rat. Clin Exp Pharmacol Physiol 2021; 48:877-889.
44. Eslamizade M, Saffarzadeh F, Mousavi S, Meftahi G, Hosseinmardi N, Mehdizadeh M, et al. Alterations in CA1 pyramidal neuronal intrinsic excitability mediated by Ih channel currents in a rat model of amyloid beta pathology. Neuroscience 2015; 305:279-292.
45. Jin S, Wang X, Xiang X, Wu Y, Hu J, Li Y, et al. Inhibition of GPR17 with cangrelor improves cognitive impairment and synaptic deficits induced by Aβ1–42 through Nrf2/HO-1 and NF-κB signaling pathway in mice. Int Immunopharmacol 2021; 101:108335.
46. Azarian F, Farsi S, Hosseini SA, Azarbayjani MA. The effect of endurance training and crocin consumption on anxiety-like behaviors and aerobic power in rats with Alzheimer’s. Iran J Psychiatry Behav Sci 2019; 13.
47. Yuan Y, Shan X, Men W, Zhai H, Qiao X, Geng L, et al. The effect of crocin on memory, hippocampal acetylcholine level, and apoptosis in a rat model of cerebral ischemia. Biomed Pharmacother 2020; 130:110543.
48. Gorman JM, Docherty JP. A hypothesized role for dendritic remodeling in the etiology of mood and anxiety disorders. J Neuropsychiatry Clin Neurosci 2010; 22:256-264.
Iranian Journal of Basic Medical Sciences
Volume 27, Issue 7
July 2024
Pages 879-887

Files

Share

How to cite

Statistics